tirzepatide ophthalmic side effects Do GLP-1 Medications Cause Eye Problems? Understanding the NAION Risk – Revolution Health & Wellness Comparative safety and side effects

Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor and glucagon-like peptide-1 (GLP-1) receptor agonist

Lilly said in an email that while both target metabolic disease, tirzepatide is a GIP/GLP-1 dual agonist injectable, whereas orforglipron is a selective, oral GLP-1 receptor agonist

Other findings included: Gallbladder issues (especially with rapid weight loss) Pancreatitis (rare, with unclear causality) Thyroid C-cell hyperplasia (in animals, not seen in humans) Lean mass lossup to 40% of weight lost may be muscle in older adults None of these derailed regulatory approvals

Buyer Takeaway: The compounded GLP-1 access window that existed from 2022 through 2025 has structurally changed